TGFβRI-IN-1, identified by its CAS number 1950628-94-0, is a small molecule inhibitor specifically targeting the transforming growth factor-beta receptor type I (TGFβRI). This compound is part of a class of inhibitors designed to modulate the TGF-β signaling pathway, which plays a crucial role in various cellular processes, including cell growth, differentiation, and immune response. TGFβRI-IN-1 is characterized by its ability to selectively inhibit TGFβRI, thereby preventing the downstream signaling that can lead to fibrosis, cancer progression, and other pathological conditions associated with aberrant TGF-β signaling. The compound is typically evaluated in preclinical studies for its efficacy in various disease models, particularly in oncology and fibrotic diseases. Its pharmacological profile includes considerations of solubility, stability, and bioavailability, which are essential for its potential therapeutic applications. As research continues, TGFβRI-IN-1 may contribute to the development of targeted therapies aimed at modulating TGF-β related diseases.

TGFβRI-IN-1

1950628-94-0: TGFβRI-IN-1, identified by its CAS number 1950628-94-0, is a small molecule inhibitor specifically targeting the transforming growth factor-beta receptor type I (TGFβRI). This compound is part of a class of inhibitors designed to modulate the TGF-β signaling pathway, which plays a crucial role in various cellular processes, including cell growth, differentiation, and immune response. TGFβRI-IN-1 is characterized by its ability to selectively inhibit TGFβRI, thereby preventing the downstream signaling that can lead to fibrosis, cancer progression, and other pathological conditions associated with aberrant TGF-β signaling. The compound is typically evaluated in preclinical studies for its efficacy in various disease models, particularly in oncology and fibrotic diseases. Its pharmacological profile includes considerations of solubility, stability, and bioavailability, which are essential for its potential therapeutic applications. As research continues, TGFβRI-IN-1 may contribute to the development of targeted therapies aimed at modulating TGF-β related diseases.

TGFβRI-IN-1 is an oral active and selective inhibitor of TGFβ receptor type I (TGFβRI) kinase(IC50 values of 2 nM and 7.6 μM for TGFβRI and TGFβRII,

CAS 1950628-94-0

TGFβRI-IN-1

TGFβRI-IN-1

Ref: TM-T13137